Douglas A. Jeffery

3.3k total citations · 1 hit paper
15 papers, 1.3k citations indexed

About

Douglas A. Jeffery is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Douglas A. Jeffery has authored 15 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 4 papers in Oncology and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Douglas A. Jeffery's work include Monoclonal and Polyclonal Antibodies Research (3 papers), Microbial Natural Products and Biosynthesis (2 papers) and Advanced Proteomics Techniques and Applications (2 papers). Douglas A. Jeffery is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (3 papers), Microbial Natural Products and Biosynthesis (2 papers) and Advanced Proteomics Techniques and Applications (2 papers). Douglas A. Jeffery collaborates with scholars based in United States, Switzerland and Singapore. Douglas A. Jeffery's co-authors include Matthew Bogyo, Amos Baruch, Paul G. Grothaus, Zhengying Pan, Paul A. Sprengeler, James T. Palmer, M. D. Sweeney, Jill M. Spoerke, Leland C. Burrill and Stacie A. Dalrymple and has published in prestigious journals such as Journal of Biological Chemistry, Angewandte Chemie International Edition and Journal of Molecular Biology.

In The Last Decade

Douglas A. Jeffery

15 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase

2006 517 citations Zhengying Pan, Heleen Scheerens et al. ChemMedChem profile →

Peers

Countries citing papers authored by Douglas A. Jeffery

Since Specialization

Citations

This map shows the geographic impact of Douglas A. Jeffery's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas A. Jeffery with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas A. Jeffery more than expected).

Fields of papers citing papers by Douglas A. Jeffery

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas A. Jeffery. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas A. Jeffery. The network helps show where Douglas A. Jeffery may publish in the future.

Co-authorship network of co-authors of Douglas A. Jeffery

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas A. Jeffery. A scholar is included among the top collaborators of Douglas A. Jeffery based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas A. Jeffery. Douglas A. Jeffery is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	US Food and Drug Administration Perspectives on Clinical Mass Spectrometry 2015 ·Clinical Chemistry ·Julia Tait Lathrop, Douglas A. Jeffery, Yvonne R. Shea, Peter F. Scholl, Maria Chan	29
2	Quantitative Proteomic Verification of Membrane Proteins as Potential Therapeutic Targets Located in the 11q13 Amplicon in Cancers 2015 ·Journal of Proteome Research ·Heather Hoover, Jun Li, Jason Marchese, Christopher Rothwell, (unknown), Douglas A. Jeffery, L. Alex Gaither, Nancy Finkel	10
3	The Natural Product Cyclomarin Kills Mycobacterium Tuberculosis by Targeting the ClpC1 Subunit of the Caseinolytic Protease 2011 ·Angewandte Chemie International Edition ·E. Schmitt, (unknown), Vasan K. Sambandamurthy, Silvio Roggo, (unknown), Christian Zwingelstein, Philipp Krastel, Christian G. Noble, David Beer, Srinivasa P. S. Rao, Melvin Au, Pornwaratt Niyomrattanakit, (unknown), Jun Zheng, Douglas A. Jeffery, Kévin Pethe, Luis R. Camacho	141
4	The Natural Product Cyclomarin Kills Mycobacterium Tuberculosis by Targeting the ClpC1 Subunit of the Caseinolytic Protease 2011 ·Angewandte Chemie ·E. Schmitt, (unknown), Vasan K. Sambandamurthy, Silvio Roggo, (unknown), Christian Zwingelstein, Philipp Krastel, Christian G. Noble, David Beer, Srinivasa P. S. Rao, Melvin Au, Pornwaratt Niyomrattanakit, (unknown), Jun Zheng, Douglas A. Jeffery, Kévin Pethe, Luis R. Camacho	15
5	“Product Ion Monitoring” Assay for Prostate-Specific Antigen in Serum Using a Linear Ion-Trap 2008 ·Journal of Proteome Research ·Vathany Kulasingam, Christopher R. Smith, Ihor Batruch, Alan Buckler, Douglas A. Jeffery, Eleftherios P. Diamandis	67
6	Development of activity-based probes for trypsin-family serine proteases 2006 ·Bioorganic & Medicinal Chemistry Letters ·Zhengying Pan, Douglas A. Jeffery, Kareem A. H. Chehade, Jerlyn Beltman, James M. Clark, Paul G. Grothaus, Matthew Bogyo, Amos Baruch	54
7	Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase breakdown → 2006 ·ChemMedChem ·Zhengying Pan, Heleen Scheerens, Shyr‐Jiann Li, Brian E. Schultz, Paul A. Sprengeler, Leland C. Burrill, Rohan Mendonca, M. D. Sweeney, (unknown), Paul G. Grothaus, Douglas A. Jeffery, Jill M. Spoerke, Lee Honigberg, Peter R. Young, Stacie A. Dalrymple, James T. Palmer	517
8	3,4-Disubstituted azetidinones as selective inhibitors of the cysteine protease cathepsin K. Exploring P3 elements for potency and selectivity 2005 ·Bioorganic & Medicinal Chemistry Letters ·Eduardo L. Setti, Dana Davis, James W. Janc, Douglas A. Jeffery, (unknown), (unknown)	25
9	Expression, Crystallization, and Three-dimensional Structure of the Catalytic Domain of Human Plasma Kallikrein 2005 ·Journal of Biological Chemistry ·Jie Tang, Christine Yu, Steven R. Williams, Eric B. Springman, Douglas A. Jeffery, Paul A. Sprengeler, Alberto Estevez, (unknown), William D. Shrader, (unknown), Wendy B. Young, Mary E. McGrath, B.A. Katz	60
10	Applications for Chemical Probes of Proteolytic Activity 2004 ·Current Protocols in Protein Science ·Matthew Bogyo, Amos Baruch, Douglas A. Jeffery, Doron C. Greenbaum, Anna Borodovsky, Huib Ovaa, Benedikt M. Kessler	6
11	Chemical proteomics and its application to drug discovery. 2004 ·PubMed ·Douglas A. Jeffery, Matthew Bogyo	5
12	Chemical proteomics and its application to drug discovery 2003 ·Current Opinion in Biotechnology ·Douglas A. Jeffery, Matthew Bogyo	173
13	Enzyme activity – it's all about image 2003 ·Trends in Cell Biology ·Amos Baruch, Douglas A. Jeffery, Matthew Bogyo	107
14	Multi-site phosphorylation of pho4 by the cyclin-CDK pho80-pho85 is semi-processive with site preference 2001 ·Journal of Molecular Biology ·Douglas A. Jeffery, Michael Springer, David S. King, Erin K. O’Shea	66
15	Functional Analysis of the Cyclin-Dependent Kinase Inhibitor Pho81 Identifies a Novel Inhibitory Domain 2001 ·Molecular and Cellular Biology ·Sidong Huang, Douglas A. Jeffery, (unknown), Erin K. O’Shea	41

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact